Published Date: 30-Nov-2022
Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
According to a new report, published by KBV research, The Global Spinal Muscular Atrophy Treatment Market size is expected to reach $11.4 billion by 2028, rising at a market growth of 17.8% CAGR during the forecast period.
The Type 2 segment is showcasing a CAGR of 18.1% during (2022 - 2028). The onset of SMA type 2 is often between the ages of 6 and 18 months. Children can sit unaided but cannot stand or walk unassisted. Children with SMA Type 2 may also experience breathing problems. Weak muscles in people with SMA, particularly type 2, prevent air from flowing easily to and from the lungs. The child might require a unique mask or mouthpiece if this occurs. The child might utilize a breathing apparatus if their issues are severe.
The Injection segment is leading the Global Spinal Muscular Atrophy Treatment Market by Route of Administration in 2021 thereby, achieving a market value of $8 billion by 2028. The growth in the segment is accountable to the great efficacy and target specificity linked to this method of administration. The majority of SMA medications on the market are administered intravenously by trained medical professionals. The injectable medicine is highly efficient in interacting with targeted genes.
The Gene Therapy segment has shown the growth rate of 20.9% during (2022 - 2028). This is because it is being used more frequently to treat spinal muscular atrophy. The introduction of a cutting-edge gene therapy solution for treating SMA symptoms boosts market expansion. For instance, the only FDA-approved gene therapy medication used to slow disease progression is Zolgensma, created by Novartis AG.
The North America market dominated the Global Spinal Muscular Atrophy Treatment Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $5.9 billion by 2028. The Asia Pacific market is exhibiting a CAGR of 19.4% during (2022 - 2028). Additionally, The Europe market would showcase a CAGR of 18.1% during (2022 - 2028).
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Biogen, Inc., Novartis AG, Ionis Pharmaceuticals, Inc., PTC Therapeutics, Inc., NMD Pharma A/S, Scholar Rock, Inc. (Scholar Rock Holding Corporation), Cytokinetics, Inc., Biohaven Pharmaceutical Holding Company Ltd. (Pfizer, Inc.), Astellas Pharma, Inc., and F. Hoffmann-La Roche Ltd. (Genentech, Inc.)
By Route of Administration
By Treatment Type
Unique Offerings from KBV Research